Literature DB >> 12440481

Intraneuronal Abeta42 accumulation in Down syndrome brain.

Chica Mori1, Edward T Spooner, Krystyna E Wisniewsk, Thomas M Wisniewski, Haruyasu Yamaguch, Takaom C Saido, Dean R Tolan, Dennis J Selkoe, Cynthia A Lemere.   

Abstract

Alzheimer's disease (AD) brains display A beta (Abeta) plaques, inflammatory changes and neurofibrillary tangles (NFTs). Converging evidence suggests a neuronal origin of Abeta. We performed a temporal study of intraneuronal Abeta accumulation in Down syndrome (DS) brains. Sections from temporal cortex of 70 DS cases aged 3 to 73 years were examined immunohistochemicallyf or immunoreactivity (IR) for the Abeta N-terminal, the Abeta40 C-terminus and the Abeta42 C-terminus. N-terminal antibodies did not detect intracellular Abeta. Abeta40 antibodies did not detect significant intracellular Abeta, but older cases showed Abeta40 IR in mature plaques. In contrast, Abeta42 antibodies revealed clear-cut intraneuronal IR. All Abeta42 antibodies tested showed strong intraneuronal Abeta42 IR in very young DS patients, especially in theyoungest cases studied (e.g., 3 or 4yr. old), but this IR declined as extracellular Abeta plaques gradually accumulated and matured. No inflammatory changes were associated with intraneuronal Abeta. We also studied the temporal development of gliosis and NFT formation, revealing that in DS temporal cortex, inflammation and NFT follow Abeta deposition. We conclude that Abeta42 accumulates intracellularly prior to extracellular Abeta deposition in Down syndrome, and that subsequent maturation of extracellular Abeta deposits elicits inflammatory responses andprecedes NFTs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12440481

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  90 in total

1.  Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model.

Authors:  Caty Casas; Nicolas Sergeant; Jean-Michel Itier; Véronique Blanchard; Oliver Wirths; Nicolien van der Kolk; Valérie Vingtdeux; Evita van de Steeg; Gwenaëlle Ret; Thierry Canton; Hervé Drobecq; Allan Clark; Bruno Bonici; André Delacourte; Jesús Benavides; Christoph Schmitz; Günter Tremp; Thomas A Bayer; Patrick Benoit; Laurent Pradier
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

2.  Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease.

Authors:  Steven E Arnold; Edward B Lee; Paul J Moberg; Lauren Stutzbach; Hala Kazi; Li-Ying Han; Virginia M Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

3.  Membrane localization of beta-amyloid 1-42 in lysosomes: a possible mechanism for lysosome labilization.

Authors:  Rui-Qin Liu; Qing-Hua Zhou; Shang-Rong Ji; Qiang Zhou; Du Feng; Yi Wu; Sen-Fang Sui
Journal:  J Biol Chem       Date:  2010-04-29       Impact factor: 5.157

4.  Critical role of intraneuronal Aβ in Alzheimer's disease: technical challenges in studying intracellular Aβ.

Authors:  Gunnar K Gouras; Katarina Willén; Davide Tampellini
Journal:  Life Sci       Date:  2012-06-19       Impact factor: 5.037

Review 5.  Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer's disease.

Authors:  Tae-In Kam; Youngdae Gwon; Yong-Keun Jung
Journal:  Cell Mol Life Sci       Date:  2014-08-24       Impact factor: 9.261

Review 6.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

7.  Long-term effect of telmisartan on Alzheimer's amyloid genesis in SHR-SR after tMCAO.

Authors:  Tomoko Kurata; Violeta Lukic; Miki Kozuki; Daisuke Wada; Kazunori Miyazaki; Nobutoshi Morimoto; Yasuyuki Ohta; Kentaro Deguchi; Toru Yamashita; Nozomi Hishikawa; Kosuke Matsuzono; Yoshio Ikeda; Tatsushi Kamiya; Koji Abe
Journal:  Transl Stroke Res       Date:  2014-01-17       Impact factor: 6.829

Review 8.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.

Authors:  D Allan Butterfield; Aaron M Swomley; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

9.  Evolution of neuroinflammation across the lifespan of individuals with Down syndrome.

Authors:  Lisi Flores-Aguilar; M Florencia Iulita; Olivia Kovecses; Maria D Torres; Sarah M Levi; Yian Zhang; Manor Askenazi; Thomas Wisniewski; Jorge Busciglio; A Claudio Cuello
Journal:  Brain       Date:  2020-12-01       Impact factor: 13.501

Review 10.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.